We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

By LabMedica International staff writers
Posted on 01 Jun 2023

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. More...

TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through tiny respiratory droplets when a TB-infected individual coughs, sneezes, or talks. Given its high contagion rate, one of the key strategies to curb TB is the early identification of infected patients, thus preventing further spread. Existing TB testing methods, while beneficial, present several drawbacks such as low sensitivity, prolonged wait times for results, and the necessity for specialized lab personnel. To combat these challenges, a research team has created a highly sensitive strip test that can detect TB within two hours.

The MTB Strip TB Test Kit developed by researchers at Chulalongkorn University (Bangkok, Thailand) leverages the technique of genetic material amplification at a constant temperature, alongside a heat box, a common piece of equipment in most labs. This approach is even accessible to small-scale hospitals. To use the MTB Strip TB Test Kit, the patient's sputum is first collected, from which DNA is extracted for use as a template. A specially-crafted primer is used to amplify the genetic material in the pathogen's DNA present in the patient's sputum, a process facilitated by a recombinase polymerase amplification technique that takes merely 20-40 minutes at 37 degrees Celsius. The resulting amplified genetic material is then introduced to the test strip, which displays positive or negative results.

The MTB Strip delivers results with an accuracy rate of up to 96% compared to Realtime PCR and other commonly used acid-resistant dye methods. Moreover, the kit proves more cost-effective than molecular biology tests as it doesn't require specific tools such as a thermocycler. Notably, the MTB Strip demonstrates high sensitivity to TB, capable of detecting even minimal amounts of TB present in sputum. Furthermore, the test is user-friendly, delivers quick and precise results within an hour that can be easily read with the naked eye, and requires no specialized equipment. Despite the satisfactory performance of the MTB Strip kit, the researchers aim to enhance its sensitivity by simplifying the DNA extraction process for use as the kit primer. Currently, they are working on expanding TB and related disease testing by creating an easier-to-use DNA extraction kit and a TB test kit capable of identifying drug-resistant TB strains from the outset, thus allowing for more specific treatment plans.

“We are currently conducting in-depth research on the genetic modification of tuberculosis using a novel technique of genetic modification for a living organism called CRISPR Cas-9 Interference to modify certain TB genes, making the infection less aggressive and more responsive to antituberculosis drugs. CRISPR Cas-9 Interference can be used in conjunction with current antituberculosis drugs,” said Dr. Panan Ratthawongjirakul, Associate Professor at Chulalongkorn University.

Related Links:
Chulalongkorn University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.